Cited by 1,810Cervical Cancer and HPV ResearchWomen's cancer prevention and managementGlobal Cancer Incidence and Screening

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials

Open access

Ronco, Guglielmo, Dillner, Joakim, Elfström, K Miriam, Tunesi, Sara, Snijders, Peter J F, Arbyn, Marc, Kitchener, Henry, Segnan, Nereo, Gilham, Clare, Giorgi-Rossi, Paolo, Berkhof, Johannes, Peto, Julian, Meijer, Chris J L M·2014·The Lancet

DOI 10.1016/s0140-6736(13)62218-7

Open this paper in CoChat — free account

Abstract

Background In four randomised trials, human papillomavirus (HPV)-based screening for cervical cancer was compared with cytology-based cervical screening, and precursors of cancer were the endpoint in every trial. However, direct estimates are missing of the relative efficacy of HPV-based versus cytology-based screening for prevention of invasive cancer in women who undergo regular screening, of modifiers (eg, age) of this relative efficacy, and of the duration of protection. We did a follow-up study of the four randomised trials to investigate these outcomes. Methods 176,464 women aged 20-64 years were randomly assigned to HPV-based (experimental arm) or cytology-based (control arm) screening in Sweden (Swedescreen), the Netherlands (POBASCAM), England (ARTISTIC), and Italy (NTCC). We followed up these women for a median of 6·5 years (1,214,415 person-years) and identified 107 invasive cervical carcinomas by linkage with screening, pathology, and cancer registries, by masked review of histological specimens, or from reports. Cumulative and study-adjusted rate ratios (experimental vs control) were calculated for incidence of invasive cervical carcinoma. Findings The rate ratio for invasive cervical carcinoma among all women from recruitment to end of follow-up was 0·60 (95% CI 0·40-0·89), with no heterogeneity between studies (p=0·52). Detection of invasive cervical carcinoma was similar between screening methods during the first 2·5 years of follow-up (0·79, 0·46-1·36) but wa…

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(13)62218-7

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,602
The 2001 Bethesda System<SUBTITLE>Terminology for Reporting Results of Cervical Cytology</SUBTITLE>
Solomon, D. (2002) · JAMA · doi:10.1001/jama.287.16.2114 · Cited by 3,104
QUANTITATIVE METHODS IN THE REVIEW OF EPIDEMIOLOGIC LITERATURE1
GREENLAND, S. (1987) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036298 · Cited by 1,644
HPV Screening for Cervical Cancer in Rural India
Sankaranarayanan, R., Nene, B. M., Shastri, S. S., Jayant, K., Muwonge, R., Budukh, A. M., Hingmire, S., Malvi, S. G., Thorat, R., Kothari, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808516 · Cited by 1,278
Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer
Mayrand, M., Duarte‐Franco, E., Rodrigues, I., Walter, S. D., Hanley, J. A., Ferenczy, A. S., Ratnam, S., Coutlée, F., & Franco, E. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071430 · Cited by 1,106
Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial
Ronco, G., Rossi, P. G., Carozzi, F., Confortini, M., Palma, P. D., Mistro, A. D., Ghiringhello, B., Girlando, S., Gillio‐Tos, A., Marco, L. D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70360-2 · Cited by 955
Self-citation
Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer
Arbyn, M., Ronco, G., Anttila, A., Meijer, C. J. L. M., Poljak, M., Ogilvie, G., Koliopoulos, G., Naucler, P., Sankaranarayanan, R., & Peto, J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.095 · Cited by 897
Self-citation
Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer
Nauclér, P., Ryd, W., Törnberg, S., Strand, A., Wadell, G., Elfgren, K., Rådberg, T., Strander, B., Johansson, B., Forslund, O., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073204 · Cited by 797
Self-citation
European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition—Summary Document
Arbyn, M., Anttila, A., Jordan, J. A., Ronco, G., Schenck, U., Segnan, N., Wiener, H., Herbert, A., & von Karsa, L. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp471 · Cited by 762
Self-citation

Show all 31 references

Sorted by citations

Items 401–500 of 1,002

A Multi-Stage Approach Combining Feature Selection with Machine Learning Techniques for Higher Prediction Reliability and Accuracy in Cervical Cancer Diagnosis
Chaudhuri, A. K., Ray, A., Banerjee, D. K., & Das, A. (2021) · International Journal of Intelligent Systems and Applications · doi:10.5815/ijisa.2021.05.05 · Cited by 31
Screening for Cervical, Prostate, and Breast Cancer
Carter, S. M., Williams, J. H., Parker, L. M., Pickles, K. M., Jacklyn, G., Rychetnik, L., & Barratt, A. L. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.01.009 · Cited by 32
Differential Detection of Human Papillomavirus Genotypes and Cervical Intraepithelial Neoplasia by Four Commercial Assays
Rebolj, M., Bonde, J. H., Preisler, S., Ejegod, D. M., Rygaard, C., & Lynge, E. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.01321-16 · Cited by 31
Circular RNAs and cervical cancer: friends or foes? A landscape on circRNA-mediated regulation of key signaling pathways involved in the onset and progression of HPV-related cervical neoplasms
Heydarnia, E., Dorostgou, Z., Hedayati, N., Mousavi, V., Yahyazadeh, S., Alimohammadi, M., Gheibi, M., Heidari, P., Igder, S., Mafi, A., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01494-0 · Cited by 30
Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology
Rebolj, M., Lynge, E., Ejegod, D. M., Preisler, S., Rygaard, C., & Bonde, J. H. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.10.014 · Cited by 30
HPV Update: Vaccination, Screening, and Associated Disease
McNamara, M., Batur, P., Walsh, J. M. E., & Johnson, K. M. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3725-z · Cited by 31
Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25–69 years living in Australia
Canfell, K., Saville, M., Caruana, M., Gebski, V., Darlington-Brown, J., Brotherton, J. M. L., Heley, S., & Castle, P. E. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-016700 · Cited by 30
Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study
El‐Zein, M., Bouten, S., Louvanto, K., Gilbert, L., Gotlieb, W. H., Hemmings, R., Behr, M. A., & Franco, E. L. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.04.004 · Cited by 30
Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening in the United States: Is It Time?
Flanagan, M. B. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0001-ra · Cited by 30
HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology
Stoler, M. H., Wright, T. C., Parvu, V., Yanson, K. A., Eckert, K., Kodsi, S., & Cooper, C. K. (2018) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqy169 · Cited by 31
The impact of age and high‐risk human papillomavirus (hrHPV) status on the prevalence of high‐grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV‐positive, cytology‐negative screening samples: a prospective cohort study
Tidy, J. A., Lyon, R., Ellis, K., Macdonald, M., & Palmer, J. (2020) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16250 · Cited by 30
The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples
Song, F., Du, H., Wang, C., Huang, X., Wu, R., & CHIMUST team (2020) · PLoS ONE · doi:10.1371/journal.pone.0234518 · Cited by 30
DNA methylation testing with S5 for triage of high‐risk HPV positive women
Adcock, R., Nedjai, B., Lorincz, A. T., Scibior‐Bentkowska, D., Banwait, R., Torrez-Martinez, N. E., Robertson, M., Cuzick, J. M., & Wheeler, C. M. (2022) · International Journal of Cancer · doi:10.1002/ijc.34050 · Cited by 30
Interobserver reproducibility of cytologic p16INK4a/Ki‐67 dual immunostaining in human papillomavirus‐positive women
Benevolo, M., Allìa, E., Gustinucci, D., Rollo, F., Bulletti, S., Cesarini, E. N., Passamonti, B. U., Giovagnoli, M. R., Carico, E., Carozzi, F., et al. (2016) · Cancer Cytopathology · doi:10.1002/cncy.21800 · Cited by 30
Self-citation
Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56–60
Lamin, H., Eklund, C., Elfström, K. M., Carlsten‐Thor, A., Hortlund, M., Elfgren, K., Törnberg, S., & Dillner, J. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-014788 · Cited by 32
Self-citation
A prospective pilot evaluation of vaginal and urine self-sampling for the Roche cobas 4800 HPV test for cervical cancer screening
Hwang, S., Shin, H. Y., Lee, D. O., Sung, N. Y., Lee, B., Lee, D. H., & Jun, J. K. (2018) · Scientific Reports · doi:10.1038/s41598-018-27390-5 · Cited by 30
Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes
Wagner, S. A., Roberson, D., Boland, J. F., Kreimer, A. R., Yeager, M., Cullen, M., Mirabello, L. J., Dunn, S. T., Walker, J. L., Zuna, R. E., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz324 · Cited by 30
Cervico-Vaginal self-collection in HIV-infected and uninfected women from Tapajós region, Amazon, Brazil: high acceptability, hrHPV diversity and risk factors
Rodrigues, L. L. S., Morgado, M. G., Sahasrabuddhe, V. V., De Paula, V. S., Oliveira, N. S., Chavez-Juan, E., Da Silva, D. M., Kast, W. M., Nicol, A. F., & Pilotto, J. H. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.08.004 · Cited by 29
Blockage of PTPRJ promotes cell growth and resistance to 5-FU through activation of JAK1/STAT3 in the cervical carcinoma cell line C33A
Yan, C., ZHAO, Y.-L., Cai, H., MIAO, G.-Y., & Ma, W. (2015) · Oncology Reports · doi:10.3892/or.2015.3769 · Cited by 29
Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework
Heard, I., Cuschieri, K. S., Geraets, D. T., Quint, W. G. V., & Arbyn, M. (2016) · Journal of Clinical Virology · doi:10.1016/j.jcv.2016.05.004 · Cited by 29
Self-citation
Candidate biomarkers in the cervical vaginal fluid for the (self-)diagnosis of cervical precancer
Ostade, X. V., Dom, M., Tjalma, W. A. A., & Raemdonck, G. V. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4587-2 · Cited by 29
Quality of life assumptions determine which cervical cancer screening strategies are cost‐effective
de Kok, I. M. C. M., Korfage, I. J., van den Hout, W. B., Helmerhorst, T. J. M., Habbema, J. D. F., Essink‐Bot, M., & van Ballegooijen, M. (2018) · International Journal of Cancer · doi:10.1002/ijc.31265 · Cited by 29
Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial
Cook, D. A., Smith, L., Law, J. H., Mei, W., Gondara, L., van Niekerk, D. J., Ceballos, K. M., Jang, D., Chernesky, M., Franco, E. L., et al. (2018) · Journal of Clinical Virology · doi:10.1016/j.jcv.2018.09.004 · Cited by 29
Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland
Vassilakos, P., Poncet, A., Catarino, R., Viviano, M., Petignat, P., & Combescure, C. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.01.021 · Cited by 29
HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the cobas 6800 in comparison to the 4800 system
Frayle, H., Gori, S., Rizzi, M., Graziani, B. N., Vian, E., Rossi, P. G., & Mistro, A. D. (2019) · BMC Women s Health · doi:10.1186/s12905-019-0743-0 · Cited by 29
Students’ Knowledge about Cervical Cancer Prevention in Poland
Osowiecka, K., Yahuza, S., Szwiec, M., Gwara, A., Kasprzycka, K., Godawska, M., Olejniczak, D., Nowacka, A., Nowakowski, J. J., Nawrocki, S., et al. (2021) · Medicina · doi:10.3390/medicina57101045 · Cited by 29
Prevalence and risk factors for High-Risk Human Papillomavirus (hrHPV) infection among HIV-infected and Uninfected Rwandan women: implications for hrHPV-based screening in Rwanda
Sinayobye, J. D., Sklar, M., Hoover, D. R., Shi, Q., Dusingize, J. C., Cohen, M. H., Mutimura, E., Asiimwe‐Kateera, B., Castle, P. E., Strickler, H. D., et al. (2014) · Infectious Agents and Cancer · doi:10.1186/1750-9378-9-40 · Cited by 30
Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women
Mistro, A. D., Frayle, H., Ferro, A. M., Callegaro, S., Sole, A. D., Stomeo, A., Cirillo, E., Fedato, C., Pagni, S., Barzon, L., et al. (2014) · Journal of Medical Screening · doi:10.1177/0969141314522219 · Cited by 29
Predictive Value of HPV Testing in Self-collected and Clinician-Collected Samples Compared with Cytology in Detecting High-grade Cervical Lesions
El‐Zein, M., Bouten, S., Louvanto, K., Gilbert, L., Gotlieb, W. H., Hemmings, R., Behr, M. A., Franco, E. L., & the CASSIS Study Group* (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-1338 · Cited by 29
HPV-based screening for cervical cancer among women 55-59 years of age
Bergengren, L., Larsson, G. L., Helenius, G., & Karlsson, M. G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217108 · Cited by 30
High-risk human papillomavirus genotype distribution among women living with and at risk for HIV in Africa
Chachage, M., Parikh, A. P., Mahenge, A., Bahemana, E., Mnkai, J., Mbuya, W., Mcharo, R. D., Maganga, L., Mwamwaja, J., Gervas, R. R., et al. (2022) · AIDS · doi:10.1097/qad.0000000000003437 · Cited by 30
Benefits and Risks of Cervical Cancer Screening
Petry, K. U., Wormann, B. J., & Schneider, A. (2014) · Oncology Research and Treatment · doi:10.1159/000365059 · Cited by 32
Characteristics of women infected with human papillomavirus in a tertiary hospital in Beijing China, 2014–2018
Ma, L., Lei, J., Ma, L., Cong, X., Wang, N., Yang, H., Liu, Q., Yu, Y., & Cao, Y. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4313-8 · Cited by 28
Clinical Performance of Human Papillomavirus (HPV) Testing versus Cytology for Cervical Cancer Screening: Results of a Large Danish Implementation Study
Thomsen, L. T., Kjær, S. K., Munk, C., Frederiksen, K., Ørnskov, D., & Waldstrøm, M. (2020) · Clinical Epidemiology · doi:10.2147/clep.s243546 · Cited by 28
Baicalein modulates the radiosensitivity of cervical cancer cells in vitro via miR-183 and the JAK2/STAT3 signaling pathway
Lei, H., Shi, J., Teng, Y., Song, C., Zou, L., Ye, F., & Zhang, H. (2021) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/135478 · Cited by 28
The experience of under-screened and never-screened participants using clinician-supported self-collection cervical screening within the Australian National Cervical Screening Program
Creagh, N. S., Zammit, C. M., Brotherton, J. M. L., Saville, M., McDermott, T. L., Nightingale, C. E., & Kelaher, M. (2022) · Women s Health · doi:10.1177/17455065221075905 · Cited by 29
Randomized Implementation of a Primary Human Papillomavirus Testing–based Cervical Cancer Screening Protocol for Women 34 to 69 Years in Norway
Nygård, M., Engesæter, B. Ø., Castle, P. E., Berland, J. M., Eide, M. L., Iversen, O. E., Jonassen, C. M., Christiansen, I. K., Vintermyr, O. K., & Tropé, A. (2022) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-22-0340 · Cited by 33
Prevention of Cervical Cancer in Low-Resource African Settings
Mulongo, M., & Chibwesha, C. J. (2022) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2022.08.008 · Cited by 30
Epidemiological study of high‑risk human papillomavirus infection in subjects with abnormal cytological findings in cervical cancer screening
You, W., Li, S., Du, R., Zheng, J., & Shen, A. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5357 · Cited by 28
Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high‐risk human papillomavirus at primary screening
Cuzick, J. M., Adcock, R., Carozzi, F., Gillio‐Tos, A., Marco, L. D., Mistro, A. D., Frayle, H., Girlando, S., Sani, C., Confortini, M., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32973 · Cited by 28
Self-citation
Human Papillomavirus Genotype Distribution in Invasive Cervical Cancer in Pakistan
Loya, A., Serrano, B., Rasheed, F., Tous, S., Hassan, M., Clavero, O., Raza, M., De Sanjosé, S., Bosch, F., & Alemany, L. (2016) · Cancers · doi:10.3390/cancers8080072 · Cited by 27
Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial
Stoler, M. H., Parvu, V., Yanson, K. A., Andrews, J. C., & Vaughan, L. M. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.04.022 · Cited by 29
Cervical human papilloma virus (HPV) DNA primary screening test: Results of a population-based screening programme in central Italy
Passamonti, B. U., Gustinucci, D., Rossi, P. G., Cesarini, E. N., Bulletti, S., Carlani, A., Martinelli, N., Broccolini, M., D’Angelo, V., D’Amico, M. R., et al. (2016) · Journal of Medical Screening · doi:10.1177/0969141316663580 · Cited by 27
Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study
Sørbye, S. W., Fismen, S., Gutteberg, T. J., Mortensen, E., & Skjeldestad, F. E. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011981 · Cited by 28
Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening
Gustavsson, I. M., Aarnio, R., Myrnäs, M., Hedlund‐Lindberg, J., Taku, O., Meiring, T. L., Wikström, I., Enroth, S., Williamson, A., Olovsson, M. H., et al. (2019) · Virology Journal · doi:10.1186/s12985-019-1216-7 · Cited by 27
Multiple sexual partners and vaginal microecological disorder are associated with HPV infection and cervical carcinoma development
Huang, Y. F., Wu, X., Lin, Y., Li, W., Liu, J., & Song, B. (2020) · Oncology Letters · doi:10.3892/ol.2020.11738 · Cited by 27
The “Sweet Spot” Revisited: Optimal Recall Rates for Cancer Detection With 2D and 3D Digital Screening Mammography in the Metro Chicago Breast Cancer Registry
Rauscher, G. H., Murphy, A. M., Qiu, Q., Dolecek, T. A., Tossas, K. Y., Liu, Y., & Alsheik, N. H. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.19.22429 · Cited by 27
Performance of a six-methylation-marker assay on self-collected cervical samples – A feasibility study
Klischke, L., von Ehr, J., Kohls, F., Kampers, J., Hülse, F., Schmitz, M., Hennig, A., Dörk, T., Hillemanns, P., & Jentschke, M. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114219 · Cited by 27
Extracellular vesicles mediated proinflammatory macrophage phenotype induced by radiotherapy in cervical cancer
Ren, J., Li, L., Yu, B., Xu, E., Sun, N., Li, X., Xing, Z., Han, X., Cui, Y., Wang, X., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09194-z · Cited by 29
HPV-Vaccine Hesitancy in Colombia: A Mixed-Methods Study
Sánchez, V. C., Lemos, M., Lopera, D. A. T., & Gorin, S. S. (2022) · Vaccines · doi:10.3390/vaccines10081187 · Cited by 27
Quality assurance in human papillomavirus testing for primary cervical screening
Cuschieri, K. S., Fellner, M. D., Mühr, L. S. A., Padalko, E. Y., Correa, R. M., Dillner, J., Gültekin, M., & Picconi, M. A. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-004197 · Cited by 26
Self-citation
Scientific approaches toward improving cervical cancer elimination strategies
Lehtinen, M., Bruni, L., Elfström, M. K., Gray, P. G., Logel, M., Mariz, F. C., Baussano, I., Vänskä, S., Franco, E. L., & Dillner, J. (2024) · International Journal of Cancer · doi:10.1002/ijc.34839 · Cited by 28
Self-citation
Comparative accuracy of Pap smear and HPV screening in Ubon Ratchathani in Thailand
Sangrajrang, S., Laowahutanont, P., Wongsena, M., Muwonge, R., Karalak, A., Imsamran, W., Senkomago, V., & Sankaranarayanan, R. (2016) · Papillomavirus Research · doi:10.1016/j.pvr.2016.12.004 · Cited by 27
History, development and future of cancer screening in Australia
Olver, I., & Roder, D. M. (2017) · Public Health Research & Practice · doi:10.17061/phrp2731725 · Cited by 27
Self-sampling for human papillomavirus DNA detection: a preliminary study of compliance and feasibility in BOLIVIA
Surriabre, P., Allende, G., Prado, M., Cáceres, L., Bellot, D., Torrico, A., Ustariz, K., Rojas, S., Barriga, J., Calle, P., et al. (2017) · BMC Women s Health · doi:10.1186/s12905-017-0490-z · Cited by 27
Human papilloma virus genotyping for the cross‐sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more
Mistro, A. D., Adcock, R., Carozzi, F., Gillio‐Tos, A., Marco, L. D., Girlando, S., Rizzolo, R., Frayle, H., Trevisan, M., Sani, C., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31326 · Cited by 28
Self-citation
Triage of high-risk HPV-positive women in population-based screening by miRNA expression analysis in cervical scrapes; a feasibility study
Babion, I., Snoek, B. C., Novianti, P. W., Jaspers, A., van Trommel, N. E., Heideman, D. A. M., Meijer, C. J. L. M., Snijders, P. J. F., Steenbergen, R. D. M., & Wilting, S. M. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0509-9 · Cited by 27
Self-citation
SEOM clinical guidelines for cervical cancer (2019)
de Juan, A., Redondo, A., Rubio, M. J., García, Y. G., Cueva, J. F., Gaba, L., Yubero, A., Alarcón, J., Maximiano, C., & Oaknin, A. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02271-z · Cited by 27
Efficacy of strategies to increase participation in cervical cancer screening: GPs offering self-sampling kits for HPV testing versus recommendations to have a pap smear taken - A randomised controlled trial
Peeters, E., Cornet, K., Devroey, D., & Arbyn, M. (2020) · Papillomavirus Research · doi:10.1016/j.pvr.2020.100194 · Cited by 27
Self-citation
Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings
Oštrbenk, A., Šterbenc, A., Seme, K., & Poljak, M. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.01120-19 · Cited by 26
HPV16 viral load and physical state measurement as a potential immediate triage strategy for HR-HPV-infected women: a study in 644 women with single HPV16 infections.
Manawapat-Klopfer, A., Wang, L. E., Haedicke, J., Stubenrauch, F., Munk, C., Thomsen, L. T., Martus, P., Kjær, S. K., & Iftner, T. (2018) · Europe PMC (PubMed Central) · Cited by 26
The Potential Benefits of HPV E6/E7 mRNA Test in Cervical Cancer Screening in China
Zhang, S., Guo, Z., Wang, P., Kang, L., Jia, M., Wu, Z., Chen, Q., Cao, X., Zhao, D., Guo, P.-P., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.533253 · Cited by 27
The role of knowledge, risk perceptions, and cues to action among Iranian women concerning cervical cancer and screening: a qualitative exploration
Asl, R. T., van Osch, L., de Vries, N. K., Zendehdel, K., Shams, M., Zarei, F., & de Vries, H. (2020) · BMC Public Health · doi:10.1186/s12889-020-09701-6 · Cited by 26
Performance of DNA methylation‐based biomarkers in the cervical cancer screening program of northern Portugal: A feasibility study
Salta, S., Maia‐Moço, L., Estevão‐Pereira, H., Sequeira, J. P., Vieira, R., Bartosch, C., Petronilho, S., Monteiro, P., Sousa, A. R., Baldaque, I., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33778 · Cited by 26
Clinical significance of extended high-risk human papillomavirus genotyping and viral load in cervical cancer and precancerous lesions
Su, P., Ma, J., Yu, L., Tang, S., & Sun, P. (2023) · Gynecology and Obstetrics Clinical Medicine · doi:10.1016/j.gocm.2023.01.001 · Cited by 27
Implications of viral infections and oncogenesis in uterine cervical carcinoma etiology and pathogenesis
Chu, D., Liu, T., & Yao, Y. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1194431 · Cited by 27
The Role of p16/Ki67 Dual Staining in Cervical Cancer Screening
Dovnik, A., & Fokter, A. R. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45100534 · Cited by 26
How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in A ustralia, a high vaccination coverage country
Velentzis, L. S., Caruana, M., Simms, K. T., Lew, J., Shi, J., Saville, M., Smith, M. A., Lord, S. J., Tan, J., Bateson, D. J., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30926 · Cited by 26
Primary HPV testing with cytology versus cytology alone in cervical screening—A prospective randomized controlled trial with two rounds of screening in a Chinese population
Chan, K. K. L., Liu, S. S., Wei, N., Ngu, S., Chu, M. M. Y., Tse, K. Y., Lau, L. S. K., Cheung, A., & Ngan, H. (2020) · International Journal of Cancer · doi:10.1002/ijc.32861 · Cited by 26
Acceptability of Self-Sampling for Human Papillomavirus-Based Cervical Cancer Screening
Chatzistamatiou, Κ., Vrekoussis, T., Tsertanidou, A., Moysiadis, T., Mouchtaropoulou, E., Pasentsis, K., Kitsou, A., Moschaki, V., Ntoula, M., Zempili, P., et al. (2020) · Journal of Women s Health · doi:10.1089/jwh.2019.8258 · Cited by 28
Human papillomavirus
Bowden, S. J., & Kyrgiou, M. (2020) · Obstetrics Gynaecology & Reproductive Medicine · doi:10.1016/j.ogrm.2020.02.003 · Cited by 25
Self-sampling to improve cervical cancer screening coverage in Switzerland: a randomised controlled trial
Viviano, M., Catarino, R., Jeannot, É., Boulvain, M., Undurraga, M., Vassilakos, P., & Petignat, P. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.111 · Cited by 25
Reducing overtreatment associated with overdiagnosis in cervical cancer screening—A model‐based benefit–harm analysis for Austria
Sroczynski, G., Esteban, E., Widschwendter, A., Oberaigner, W., Borena, W., von Laer, D., Hackl, M., Endel, G., & Siebert, U. (2019) · International Journal of Cancer · doi:10.1002/ijc.32849 · Cited by 25
Concerns about disclosing a high-risk cervical human papillomavirus (HPV) infection to a sexual partner: a systematic review and thematic synthesis
Bennett, K. F., Waller, J., Ryan, M., Bailey, J., & Marlow, L. A. V. (2020) · BMJ Sexual & Reproductive Health · doi:10.1136/bmjsrh-2019-200503 · Cited by 25
Assessing 10-Year Safety of a Single Negative HPV Test for Cervical Cancer Screening: Evidence from FOCAL-DECADE Cohort
Gottschlich, A., van Niekerk, D., Smith, L., Gondara, L., Melnikow, J. A., Cook, D. A., Lee, M. H., Stuart, G. C. E., Martin, R. E., Peacock, S. J., et al. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-1177 · Cited by 25
Women's critical experiences with the pap smear for the development of cervical cancer screening devices
Arrivillaga, M., Bermúdez, P. C., García-Cifuentes, J. P., Rodríguez‐López, M., Neira, D., & Cardona, H. D. V. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14289 · Cited by 24
Effectiveness of workplace cancer screening interventions: a systematic review
Mon, H. M., Robb, K. A., & Demou, E. (2024) · BMC Cancer · doi:10.1186/s12885-024-12649-0 · Cited by 30
Clinical indications for host-cell DNA methylation markers in cervical screening and management of cervical intraepithelial neoplasia: A review
Dick, S., Heideman, D. A. M., Berkhof, J. H., Steenbergen, R. D. M., & Bleeker, M. C. G. (2024) · Tumour Virus Research · doi:10.1016/j.tvr.2024.200308 · Cited by 24
Self-citation
Clinical Validation of a Vaginal Cervical Cancer Screening Self-Collection Method for At-Home Use
Fitzpatrick, M. B., Behrens, C. M., Hibler, K., Parsons, C., Kaplan, C., Orso, R., Parker, L., Memmel, L. M., Collins, A., McNicholas, C. P., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.11081 · Cited by 27
Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended?
Vink, M. A., Bogaards, J. A., Meijer, C. J. L. M., & Berkhof, J. H. (2014) · International Journal of Cancer · doi:10.1002/ijc.29381 · Cited by 24
Self-citation
Human papillomavirus vaccination: Where are we now?
Brotherton, J. M. L. (2014) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.12627 · Cited by 25
Self-Sampling for Cervical Cancer Screening: Empowering Women to Lead a Paradigm Change in Cancer Control
Franco, E. L. (2018) · Current Oncology · doi:10.3747/co.25.3969 · Cited by 25
Gebärmutterhalskrebsscreening in Deutschland
Meuer, J., & Klug, S. J. (2018) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-018-2835-7 · Cited by 24
Clinical impact and cost-effectiveness of primary cytology versus human papillomavirus testing for cervical cancer screening in England
Bains, I., Choi, Y. H., Soldan, K., & Jit, M. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2018-000161 · Cited by 24
Cost-effectiveness of cervical cancer screening with primary HPV testing for unvaccinated women in Sweden
Fogelberg, S., Clements, M., Pedersen, K., Sy, S., Sparén, P., Kim, J. J., & Burger, E. A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239611 · Cited by 26
Self‐sampling as the principal modality for population based cervical screening: Five‐year follow‐up of the PaVDaG study
Stanczuk, G. A., Currie, H. D., Forson, W., Baxter, G. J., LAWRENCE, J. R., Wilson, A., Palmer, T. J., Arbyn, M., & Cuschieri, K. S. (2021) · International Journal of Cancer · doi:10.1002/ijc.33888 · Cited by 25
Self-citation
A low-cost, paper-based hybrid capture assay to detect high-risk HPV DNA for cervical cancer screening in low-resource settings
Smith, C. A., Chang, M. M., Kundrod, K. A., Novak, E. N., Parra, S. G., López, L., Mavume, C., Lorenzoni, C. F., Maza, M., Salcedo, M. P., et al. (2022) · Lab on a Chip · doi:10.1039/d2lc00885h · Cited by 25
PCDHGB7 hypermethylation-based Cervical cancer Methylation (CerMe) detection for the triage of high-risk human papillomavirus-positive women: a prospective cohort study
Cao, D., Yang, Z., Dong, S., Li, Y., Mao, Z., Lu, Q., Xu, P., Shao, M., Pan, L., Han, X., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03267-5 · Cited by 24
Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women
Luttmer, R., Berkhof, J. H., Dijkstra, M. G., van Kemenade, F. J., Snijders, P. J. F., Heideman, D. A. M., & Meijer, C. J. L. M. (2015) · Journal of Clinical Virology · doi:10.1016/j.jcv.2015.04.004 · Cited by 25
Self-citation
Laboratory audit as part of the quality assessment of a primary HPV-screening program
Hortlund, M., Sundström, K., Lamin, H., Hjerpe, A., & Dillner, J. (2015) · Journal of Clinical Virology · doi:10.1016/j.jcv.2015.12.007 · Cited by 24
Self-citation
Tyrosine kinase LYN is an oncotarget in human cervical cancer: A quantitative proteomic based study
Liu, S., Hao, X., Ouyang, X., Dong, X., Yang, Y., Yu, T., Hu, J., & Hu, L. (2016) · Oncotarget · doi:10.18632/oncotarget.12258 · Cited by 24
Follow-up of women with cervical cytological abnormalities showing atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion: a nationwide cohort study
Sundström, K., Lu, D., Elfström, K. M., Wang, J., Andrae, B., Dillner, J., & Sparén, P. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2016.07.042 · Cited by 24
Self-citation
Efficacy of self-sampling in promoting participation to cervical cancer screening also in subsequent round
Mistro, A. D., Frayle, H., Ferro, A. M., Fantin, G. P., Altobelli, E., & Rossi, P. G. (2016) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2016.12.017 · Cited by 24
Projected impact of HPV vaccination and primary HPV screening on cervical adenocarcinoma: Example from Australia
Smith, M. A., & Canfell, K. (2017) · Papillomavirus Research · doi:10.1016/j.pvr.2017.04.003 · Cited by 24
Acceptability of Self-Sample Human Papillomavirus Testing Among Thai Women Visiting a Colposcopy Clinic
Phoolcharoen, N., Kantathavorn, N., Krisorakun, W., Taepisitpong, C., Krongthong, W., & Saeloo, S. (2018) · Journal of Community Health · doi:10.1007/s10900-017-0460-2 · Cited by 24
Diagnostic value of human papillomavirus (HPV) 16 and HPV18 viral loads for the detection of high-grade cervical intraepithelial neoplasia (CIN2+) in a cohort of African women living with HIV
Segondy, M., Ngou, J., Kelly, H. A., Omar, T., Goumbri-Lompo, O., Doutre, S., Mayaud, P., & Didelot, M.-N. (2018) · Journal of Clinical Virology · doi:10.1016/j.jcv.2018.01.006 · Cited by 24
Implementation of HPV ‐based cervical cancer screening in an organised regional screening programme: 3 years of experience
Veijalainen, O., Kares, S., Kujala, P. M., Vuento, R., Osuala, V., Tirkkonen, M., Luukkaala, T. H., Kholová, I., & Mäenpää, J. (2018) · Cytopathology · doi:10.1111/cyt.12652 · Cited by 24
The Prevalence, Anatomic Distribution and Significance of HPV Genotypes in Head and Neck Squamous Papillomas as Detected by Real-Time PCR and Sanger Sequencing
Trzcinska, A., Zhang, W., Gitman, M., & Westra, W. (2019) · Head and Neck Pathology · doi:10.1007/s12105-019-01057-7 · Cited by 24
Performance of Two-Stage Cervical Cancer Screening With Primary High-Risk Human Papillomavirus Testing in Women Living With Human Immunodeficiency Virus
Luckett, R. L., Mogowa, N., Li, H. J., Erlinger, A. L., Hacker, M. R., Esselen, K. M., Feldman, S., Shapiro, R., Morroni, C., & Ramogola‐Masire, D. (2019) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003496 · Cited by 25
Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation
Weston, G., Dombrowski, C., Harvey, M. J., Iftner, T., Kyrgiou, M., Founta, C., & Adams, E. J. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-031303 · Cited by 24

Authors: Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J. F., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., Berkhof, J., Peto, J., & Meijer, C. J. L. M.
Affiliations: Karolinska Institutet (SE)
Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Institut Scientifique de Santé Publique (BE)
University of Manchester (GB)
Centre international de recherche sur le cancer (FR)
London School of Hygiene & Tropical Medicine (GB)
Corresponding author: Ronco, Guglielmo
ORCID: Ronco, Guglielmo
Dillner, Joakim
Elfström, K Miriam
Snijders, Peter J F
Arbyn, Marc
Kitchener, Henry
Segnan, Nereo
Gilham, Clare
Berkhof, Johannes
Peto, Julian
Meijer, Chris J L M
Venue: The Lancet
Publisher: Elsevier BV
Published: 2014-02
Volume: 383
Issue: 9916
Pages: 524-532
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(13)62218-7
OpenAlex: W2121732950
Cited by: 1,810
References: 31
Citations by year: 2026: 136 · 2025: 141 · 2024: 166 · 2023: 150 · 2022: 140 · 2021: 149 · 2020: 161 · 2019: 152 · 2018: 130 · 2017: 131 · 2016: 131 · 2015: 129 · 2014: 83
FWCI: 84.20
Type: journal article
Language: en
Open access: green
zenodo.org
Licence: other-oa
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Research Explorer (The University of Manchester) (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
LSHTM Research Online (London School of Hygiene and Tropical Medicine) (submittedVersion)
Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: PREDHICT project (242061)
Topics: Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
Keywords: HPV-based cervical cancer screening, invasive cervical cancer, cytology-based screening, cancer prevention, screening efficacy, duration of protection, cervical cancer incidence, cervical cancer screening guidelines
MeSH terms: Adult, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Colposcopy, Cytological Techniques, Europe, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Invasiveness, Precancerous Conditions, Multicenter Studies as Topic, Incidence, Randomized Controlled Trials as Topic, Papillomavirus Infections, Early Detection of Cancer, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks